Analysis of the ERK1,2 transcriptome in mammary epithelial cells.
MAPK (mitogen-activated protein kinase) pathways constitute major regulators of cellular transcriptional programmes. We analysed the ERK1,2 (extracellular-signal-regulated kinase 1,2) transcriptome in a non-transformed MEC (mammary epithelial cell) line, MCF-12A, utilizing rAd MEK1EE, a recombinant adenovirus encoding constitutively active MEK1 (MAPK/ERK kinase 1). rAd MEK1EE infection induced morphological changes and DNA synthesis which were inhibited by the MEK1,2 inhibitor PD184352. Hierarchical clustering of data derived from seven time points over 24 h identified 430 and 305 co-ordinately up-regulated and down-regulated genes respectively. c-Myc binding sites were identified in the promoters of most of these up-regulated genes. A total of 46 candidate effectors of the Raf/MEK/ERK1,2 pathway in MECs were identified by comparing our dataset with previously reported Raf-1-regulated genes. These analyses led to the identification of a suite of growth factors co-ordinately induced by MEK1EE, including multiple ErbB ligands, vascular endothelial growth factor and PHRP (parathyroid hormone-related protein). PHRP is the primary mediator of humoral hypercalcaemia of malignancy, and has been implicated in metastasis to bone. We demonstrate that PHRP is secreted by MEK1EE-expressing cells. This secretion is inhibited by PD184352, but not by ErbB inhibitors. Our results suggest that, in addition to anti-proliferative properties, MEK1,2 inhibitors may be anti-angiogenic and possess therapeutic utility in the treatment of PHRP-positive tumours.
Grill
Constance
C
Biological Research-Oncology, Schering-Plough Research Institute, Kenilworth, NJ 07033, USA.
Gheyas
Ferdous
F
Dayananth
Priya
P
Jin
Weihong
W
Ding
Wei
W
Qiu
Ping
P
Wang
Luquan
L
Doll
Ronald J
RJ
English
Jessie M
JM
D000256:Adenoviridae / Q000235:genetics; D017209:Apoptosis / Q000235:genetics; D001665:Binding Sites / Q000235:genetics; D001940:Breast / Q000166:cytology* / Q000201:enzymology*; D002453:Cell Cycle / Q000502:physiology; D002460:Cell Line; D002874:Chromosome Mapping / Q000379:methods; D003599:Cytoskeleton / Q000201:enzymology / Q000378:metabolism; D004260:DNA Repair / Q000235:genetics; D054638:Dual Specificity Phosphatase 1; D004847:Epithelial Cells / Q000201:enzymology*; D015971:Gene Expression Regulation, Enzymologic / Q000235:genetics / Q000502:physiology; D005796:Genes / Q000502:physiology; D019398:Genes, BRCA1 / Q000502:physiology; D024522:Genes, BRCA2 / Q000502:physiology; D017781:Genes, Immediate-Early / Q000235:genetics; D005822:Genetic Vectors / Q000096:biosynthesis; D006801:Humans; D048369:MAP Kinase Kinase 1 / Q000235:genetics / Q000502:physiology; D019950:Mitogen-Activated Protein Kinase 1 / Q000235:genetics* / Q000502:physiology; D048052:Mitogen-Activated Protein Kinase 3 / Q000235:genetics* / Q000502:physiology; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D054645:Protein Phosphatase 1; D017027:Protein Tyrosine Phosphatases / Q000235:genetics / Q000502:physiology; D019908:Proto-Oncogene Proteins c-raf / Q000235:genetics; D014157:Transcription Factors / Q000235:genetics; D014158:Transcription, Genetic
D014157:Transcription Factors; D019908:Proto-Oncogene Proteins c-raf; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D048369:MAP Kinase Kinase 1; D054645:Protein Phosphatase 1; C517019:DUSP1 protein, human; D054638:Dual Specificity Phosphatase 1; D017027:Protein Tyrosine Phosphatases